Redeye: Proact - Initiatives to Counter Cost Inflation
Redeye retains its positive view of Proact despite somewhat reducing our Base Case and 2023-2024 EBITA forecasts. Sales were solid in the quarter, with the highlight being 8% organic growth in recurring revenue. However, cost inflation hurt margins, which Proact has not yet fully compensated for, mostly due to its three years Cloud and Support contracts.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/